2011 - Athens - Greece

Software demonstrations: Olympia foyer (Level -1)

Kajsa Harling Perl speaks NONMEM (PsN) and Xpose
Marc Lavielle Analysing population PK/PD data with MONOLIX 4.0
Joakim Nyberg PopED - An optimal experimental design software
Coen van Hasselt Piraña: The flexible modeling environment for NONMEM
Stephane Vellay Pipeline Pilot - Data Integration, Analysis, and Reporting Platform

Posters: Absorption and physiology-based PK

I-10 Christian Bartels Population PK Model for Pooled Data of Different Oral Diclofenac Formulations
I-35 Vicente G. Casabo Bioequivalence trials simulation to select the best analyte for acetylsalicylic acid
I-62 Kristin Dickschen Pharmacogenomics of Tamoxifen In Female Patients: A PBPK Model-based Investigation Including The Three Main Metabolites
II-20 Ludivine Fronton Monoclonal Antibody Disposition beyond Target Binding: Impact of FcRn on Clearance and Derivation of Mechanistic Compartment Models
II-40 Emilie Hénin Meta-analysis of Magnetic Marker Monitoring data to characterize tablet movement through the gastrointestinal tract
III-9 Donghwan Lee Development of a population model to describe diurnal and chronokinetic variation in cilostazol pharmacokinetics
III-26 Eugeniy Metelkin A Systems Pharmacology Model of Anandamide Dynamics After FAAH Inhibitor Administration
III-35 Christoph Niederalt Development of a detailed physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in rats
III-40 Kayode Ogungbenro A semi-mechanistic gastric emptying pharmacokinetic model for 13C-octanoic acid: an evaluation using simulation
III-54 Anna Pieper Development of a PBPK model of doxorubicin
IV-8 Alexander Solms Modelling Inter-Individual Variability in PBPK Models and Deriving Mechanistic Covariate Models for PopPK
IV-21 Sonya Tate The Importance of Enterohepatic Recirculation in the Disposition of Pravastatin and Rosuvastatin: A Physiologically-Based Pharmacokinetic Modelling Approach
IV-47 Thomas Wendl Development of a physiologically-based pharmacokinetic (PBPK) model for Moxifloxacin and its metabolites in healthy adults
IV-65 Kirill Zhudenkov Pharmacokinetics of PEG-IFN Alpha in HCV Infected Patients

Posters: Cardiovascular, QT-prolongation

I-14 Francesco Bellanti Relevance of QT-RR correlations in the assessment of QTc-interval prolongation in clinical trial simulations
I-28 Christine Brandquist PK/PD Modeling of the Effect of Intravenous Doses of Anzemet® (dolasetron mesylate) and Its Metabolite (hydrodolasetron) on the QT Interval in Healthy Subjects
I-37 Anne Chain Can First-Time-In-Human Trials Replace Thorough QT Studies?
I-63 Jeroen Diepstraten Pharmacodynamics of nadroparin using anti-Xa levels in morbidly obese patients upon subcutaneous administration of 5700 IU
II-1 Vincent Dubois Translation of drug-induced QTc prolongation in early drug development.
II-11 Farkad Ezzet Meta-Analysis of Antiplatelets in Patients with Atrial Fibrillation: A survival Model
II-44 Eleanor Howgate PKPD Modelling Of Cardiovascular Safety Pharmacology Data
II-55 Helene Karcher Probabilistic risk assessment for QT prolongation and heart rate increase
III-41 Oliver Ackaert  Population modelling of blood pressure: assessing clinically important factors for cardiovascular diseases
IV-6 Nelleke Snelder Quantitative understanding of drug effects on the interrelationship between mean arterial blood pressure, cardiac output and total peripheral resistance
IV-36 Piet van der Graaf Towards a Thorough Preclinical QT (“TpQT”) study paradigm: Pharmacokinetic-Pharmacodynamic (PKPD) Modelling of QTc Effects of Moxifloxacin in Cynomolgus Monkeys

Posters: CNS

I-22 Irina Bondareva Sequential Interacting Multiple Model (IMM) Bayesian Analysis of Carbamazepine and Valproate Repeated Therapeutic Drug Monitoring (TDM) Data from Epileptic Patients
I-32 Jacob Brogren Separate vs. simultaneous analysis of co-primary endpoints in Alzheimer’s disease clinical trials
I-56 Elizabeth de Lange Mechanism-based PK-PD model of remoxipride with rat-to-human extrapolation: characterizing remoxipride target site PK and systems homeostatic feedback
II-25 Martin Gnanamuthu Johnson Predicting Dopamine D2 Receptor Occupancy in humans using a physiology-based approach
II-26 Martin Gnanamuthu Johnson Pharmacokinetic-Pharmacodynamic Modeling of Dopamine D2 Receptor Occupancy in humans using Bayesian modeling tools
II-34 Zheng Guan Population pharmacokinetic and pharmacodynamic analysis of cortisol in serum and saliva in healthy male volunteers after an acute 5-hydroxytryptophan (5-HTP) challenge test
II-42 Eef Hoeben Population pharmacokinetic analysis of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia
II-48 Masoud Jamei A physiologically-based pharmacokinetic (PBPK) brain model and its application in simulating drug disposition in brain
II-65 Huub Jan kleijn Development and Application of a Semi-Mechanistic Model for Modulation of Amyloid-beta in Cerebrospinal Fluid after Inhibition of γ-secretase.
III-16 Arianna Madrid Modelling the sleep effects of Zolpidem in rats using non-homogeneous Markov chain models
III-25 François Mercier A Bayesian meta-analysis of longitudinal lesion count data in multiple sclerosis patients
III-56 Venkatesh Pilla Reddy Exposure-Response Relationship of Typical and Atypical Antipsychotics Assessed by the Positive and Negative Syndrome Scale (PANSS) and its Subscales
III-58 Bart Ploeger Confirmation of symptomatic and disease modifying effects of levodopa using the ELLDOPA study
IV-15 Ahmed Suleiman A Mixed-Effects Markov Model for Characterizing the Time Course of the Transitions between Different Extrapyramidal Side Effects Severity Levels
IV-19 Stina Syvänen Quinidine Microdialysis Reveals Altered P-glycoprotein Function in Epileptic Rats in the Brain Parenchyma Rather than at the Blood-Brain Barrier
IV-30 Karin Tunblad A pharmacokinetic/pharmacodynamic analysis of central and peripheral effects of GSK3 inhibitors 

Posters: Endocrine

I-45 Steve Choy Application of an integrated glucose-insulin model to investigate the effects of glibenclamide and its active metabolites on postprandial glucose and insulin concentrations in healthy volunteers
II-7 Petra Ekerot Mechanism-based Pharmacokinetic-Pharmacodynamic Feedback Model of Thyroid Hormones after Inhibition of Thyroperoxidase in the Dog. Cross-species Prediction of Thyroid Hormone Profiles in Rats and Humans.
III-6 Anna Largajolli Meal Tolerance Test (MTT): Nonlinear Mixed-Effects Modeling of Insulin Secretion
III-29 Jonas Bech Møller Model-based Analysis of the GLP-1 Response following an Oral Glucose Tolerance Test (OGTT)
III-46 Joanna Peng A Mechanistic Model for the Effects of A Novel Drug on Glucose, Glucagon and Insulin Applied to Adaptive Phase II Design
III-49 Kirill Peskov A Quantitative Systems Pharmacology Model Provides Insights into Phosphate Homoeostasis through Multiple Interacting Pathways
IV-37 Piet van der Graaf Application of a Multiscale Physiologically-Based Bone and Calcium Systems Model to Guide the Development of GnRH receptor modulators for the Management of Endometriosis
IV-59 Stefan Zajic Semi-mechanistic PK/PD Model of the Effect of Odanacatib, a Cathepsin K Inhibitor, on Bone Turnover to Characterize Lumbar Spine and Distal Forearm Bone Mineral Density in Two Phase II Studies of Postmenopausal Women

Posters: Estimation methods

I-29 Karl Brendel A comparison of MONOLIX, NONMEM 6 and NONMEM 7 based on a simulated PK example
I-44 Jason Chittenden Evaluation of the Lindstrom-Bates FOCE Algorithm with Simulated Pharmacokinetic Datasets
I-50 Emmanuelle Comets SAEMIX, an R version of the SAEM algorithm
I-54 Alexander Danis Set-valued methods for estimation of parameters in population models
II-29 Helen Graham Development of a novel method for updating the predicted partition coefficient values generated by an existing in silico prediction method
III-8 Robert Leary Exact Reproducibility of Population PK/PD NLME Numerical Results across Different Computational Environments
III-42 Erik Olofsen Population Analysis of Kalman-Filtered Permutation Entropy of the Electroencephalogram
III-43 Itziar Oteo Differences among six prevalent creatinine clearance calculation methods by covariate modeling of CL for Netilmicin using NONMEM for inference
IV-41 Georgios Vlasakakis The impact of modified-release formulations on bridging of pharmacokinetic data from adults to children

Posters: Infection

I-2 Mona Alameddine Population Pharmacokinetic Analysis and Effects of Raltegravir In HIV positive and Healthy Individuals
I-3 Sarah Alghanem Development of a Tobramycin Dosage Adjustment Nomogram for Patients with Cystic Fibrosis
I-16 Julie Bertrand Extensive Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients
I-30 Margreke Brill Cefazolin pharmacokinetics in morbidly obese patients following a prophylactic dose during weight reducing surgery.
I-39 Georgia Charkoftaki Pharmacokinetics of doripenem in cerebrospinal fluid
I-46 Christine Xu Population Pharmacokinetics (PPK) and Pharmacokinetic-Pharmacodynamic (PK/PD) of Vicriviroc in Treatment Naive HIV
I-60 Paolo Denti Population PK of Isoniazid in South African Adults.
II-17 Monika Frank Integrated Population Pharmacokinetic Model Development of Nevirapine for Mothers and Newborns including Healthy Male Volunteer Data
II-22 Maria Garrido Population Pharmacokinetics/Pharmacodynamics of Ganciclovir after Intravenous Ganciclovir and Oral Valganciclovir Administration in SOT Patients Infected with CMV
II-27 Sylvain Goutelle Comparison of Four Renal Function Estimator-Based Models for the Prediction of Gentamicin Concentrations in Geriatric Patients by Use of Nonparametric Population Approach
II-35 Monia Guidi Population Pharmacokinetics of Nevirapine in HIV-positive Patients
II-43 Richard Höglund Population modelling of the pharmacokinetics of a mefloquine-artesunate treatment at the Thai-Myanmar border
II-46 Arantxa Isla Population Pharmacokinetics of Cefoxitin as a Prophylactic Antimicrobial Agent
II-60 Dalia Khachman Optimising ciprofloxacin dosing in intensive care patients based on pharmacodynamic target attainment
II-61 David Khan PKPD-modeling of time-kill curves from E. coli mutants exposed to ciprofloxacin
III-5 Ryuji Kubota A Novel Framework of Long-term Prediction of integrase inhibitors for treatment naïve patients
III-36 Elisabet Nielsen PK/PD Indices of Antibiotics Predicted by Mechanism-Based PKPD Models
III-63 Dinko Rekic Bilirubin - a biomarker of atazanavir exposure in HIV/AIDS patients
IV-4 Andre Schäftlein Comparison of elimination and absorption pharmacokinetics of linezolid in cystic fibrosis patients by three nonlinear models
IV-9 Ivy Song Applications of Population Pharmacokinetic Modeling during Phase2B to Support the Clinical Development of Dolutegravir (DTG, S/GSK1349572)
IV-12 Joe Standing Methods for Optimising Neonatal Antimicrobial Use: Time- and Concentration-Dependent Agents
IV-16 Elin Svensson Mega-model of nevirapine population pharmacokinetics
IV-17 Vinogradova Svetlana Applying of population PK-PD methods to analysis of viral dynamics of HIV/HCV-Coinfected Sustained Virological Responders and Nonresponders treated with PEG-IFN
IV-18 Ami Fazlin Syed Mohamed Pharmacokinetic-Pharmacodynamic Modelling of Pre-existing and Emerging Resistance of Pseudomonas aeruginosa to Colistin
IV-34 Marta Valle Effect of Ritonavir Concentrations on Atazanavir Pharmacokinetics: Population Pharmacokinetic Analysis
IV-35 Georgia Valsami Assessment of dosage regimens of tigecycline in hospitalised patients
IV-38 Jan-Stefan van der Walt The effect of nevirapine-based antiretroviral therapy on the population pharmacokinetics of artemether and dihydroartemesinin in HIV-infected adults
IV-42 Max von Kleist A Mathematical Modelling Framework to Assess the Impact of Nevirapine-based Prophylaxis on vertical HIV Transmission
IV-45 Toshihiro Wajima Pharmacokinetic/pharmacodynamic Modeling and Long-term Simulation of Dolutegravir (DTG, S/GSK1349572) in Integrase Resistant Patients with a Simple Viral Dynamic Model
IV-54 Hongmei Xu Mechanism-based Modelling of the Antagonism between Polymyxin B and Levofloxacin against Pseudomonas aeruginosa using Mono- and Combination Therapy
IV-57 James Yates Population PK/PD modelling of AZD9773 in patients with severe sepsis.
IV-62 Chao Zhang Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Adults
IV-66 Simbarashe Peter Zvada Population Pharmacokinetics of Isoniazid in Children with Pulmonary Tuberculosis

Posters: Inflammation

II-24 Leonid Gibiansky Mechanistic Modeling of the Link between Interleukin 6 Receptor Blockade with Tocilizumab and Its Hematological Effects
III-1 Gilbert Koch Semi-mechanistic modelling of collagen-induced arthritis in mice and of the effect of administration of an anti-Granulocyte Macrophage Colony-Stimulating Factor antibody using delay differential equations
III-55 Etienne Pigeolet Population PKPD modeling of dose-response and time course of peripheral lymphocytes after single and repeated administration of the S1P1/5 modulator, BAF312, in healthy volunteers.
IV-61 Miren Zamacona Model based approach to inform early clinical development for a biologic

Posters: Model evaluation

I-51 Emmanuelle Comets Prediction discrepancies (pd) for evaluation of models with data under limit of quantification
II-33 Namyi Gu Population Pharmacokinetics of a new TRPV1 antagonist in healthy volunteers.
II-49 Masoud Jamei Modelling the Effect of Interleukin-6, an Inflammatory Cytokine, on Time-dependent Reduction of Cyclosporine Clearance: An Application of the Simcyp Population-based Simulator to Suppression of CYP450 by Biologics
III-7 Marc Lavielle Improved diagnostic plots require improved statistical tools. Implementation in MONOLIX 4.0
III-10 Annabelle Lemenuel-Diot External evaluation of a Hepatitis C viral kinetic model which links viral dynamics to sustained virologic response (SVR)
III-51 Klas Petersson Assessment of bias in model parameter estimates of continuous time Markov models for categorical data

Posters: Oncology

I-6 Orna Amir Predictive Model for Identification of Responders/Non Responders in Metastatic Breast Cancer Patients Treated with Docetaxel
I-15 Brendan Bender A semi-mechanistic population Pharmacokinetic-Pharmacodynamic (PKPD) model of thrombocytopenia characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
I-21 Michael Block Mechanistic PBPK/PD modeling for prediction of study outcome of cancer therapies: Translating in-vitro information into valid in-vivo predictions
I-23 Guillaume BONNEFOIS A nonlinear mixed effect model to study albumin-mediated drug transport into endothelial cells in vitro.
I-24 Stephan Borghorst Age Dependent Volume of Distribution of Pegylated Asparaginase (OncasparTM) in children and adults
II-9 Fernandez Eric Using the Virtual Tumour to predict and optimize drug combination regimens
II-14 Gregory Ferl Population analysis of the DCE-MRI response of liver metastases to a single dose of bevacizumab in CRC patients
II-16 Nicolas Frances Integrating distribution to tumor tissue into a dynamic PK/PD model to evaluate the anti-cancer effect of erlotinib in patient-derived LXFA 677 tumor xenograft mice
II-28 Iztok Grabnar Bayesian Estimation of Methotrexate Pharmacokinetics in Children with Acute Lymphoblastic Leukaemia and Prediction of Folinic Acid Rescue
II-31 Joachim Grevel A physiology-based model predicts pharmacokinetics, target occupancy in the tumour, and HSP70 biomarker response in serum for the HSP90 inhibitor, 17-AAG
II-36 Neeraj Gupta Population PK and PK/PD Analysis of Intravenous Investigational Agent MLN9708 in Solid Tumors and Lymphoma Patients
II-52 Jin Jin Mechanism-Based Population Pharmacokinetic (PK) Modeling of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449), a Novel Molecule with Unique PK Nonlinearity in Humans
III-4 Steve Kuan Population Pharmacokinetic Modeling of Investigational Agent MLN4924 in Cancer Patients 
III-17 Paolo Magni A new population PK/PD model to assess the myelotoxicity of candidate drugs in preclinical and in clinical studies
III-21 Maria Matoses Osborne Ex Vivo modeling of the apoptotic effects of Vivia009 and its metabolite in patients with Chronic Lymphocytic Leukemia
III-30 Daniele Morpurgo Predicting the Gemcitabine efficacy by a stochastic language based model
III-34 Ronald Niebecker Importance of study design for estimation of Vmax and Km characterising nonlinear monoclonal antibody clearance
III-37 Valerie Nock Leukopenia following triple high-dose chemotherapy and stem cell rescue
III-50 Kirill Peskov Systems Modeling of EphB4/ephrinB2 Signaling Pathways
IV-3 Franziska Schädeli Stark A semi-mechanistic population pharmacokinetic model for trastuzumab emtansine (T-DM1) antibody-drug conjugate and total antibody in patients with metastatic breast cancer (mBC)
IV-11 Alexandre Sostelly Characterization of the interaction between irinotecan, SN-38 and MBLI-87, a new BCRP inhibitor, with a multi-scale semi-mechanistic PKPD model
IV-27 Mirjam Trame Busulfan Dosing in Children: Body Weight versus Body Surface Area or Allometric Body Weight Dosing
IV-50 Mélanie Wilbaux Population KPD modelling of CA125 and tumor size in patients with ovarian cancer
IV-58 James Yates Characterisation of Xenograft Response to Docetaxel by Nonlinear Mixed Effects Modelling
IV-63 Jianping Zhang Population Pharmacokinetics of Lapatinib in Cancer Patients

Posters: Other drugs and diseases

I-5 Claire Ambery Modelling impact of dropout mechanisms in Chronic Obstructive Pulmonary Disease (COPD)
I-9 Jacqueline Anderson Comparative pharmacokinetics of dimethoate poisoning in the minipig and human
I-49 Adriaan Cleton Population Pharmacokinetics of a Monoclonal Antibody Tanezumab in Chronic Pelvic Pain Conditions
II-23 Cecile Gerard Factors influencing pharmacokinetics of tacrolimus during the early liver post-transplantation period: a population analysis
III-2 Julia Korell Modelling red blood cell survival data
III-28 Dirk Jan Moes Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients on a calcineurin inhibitor free regimen
III-47 Mark Penney Using Mechanistic Modelling of Cyclic Neutropenia to Predict the Effects of a COPD Therapeutic on Systemic Neutrophil Levels
III-48 Henry Pertinez Physiologically based, POP-PK modelling of a bone seeking agent in the ovariectomised rat disease model of post menopausal osteoporosis.
IV-5 Rik Schoemaker Modelling Ordered Categorical Allergic Rhinitis Scores in an Environmental Exposure Unit Study
IV-40 Erno van Schaick PK-PD modelling of bone density and turnover effects of denosumab based on a circular model of bone remodelling
IV-51 Christian Woloch Population Pharmacokinetics of Mefloquine and its Major Metabolite in Healthy Volunteers.

Posters: Other topics - Applications

I-41 Marylore Chenel Developing an In Vitro – In Vivo Correlation Model Using a Population Approach in NONMEM
I-47 Jae Yong Chung Modelling of Atorvastatin Pharmacokinetics in relation to SLCO1B1 genotype and Simulations for Bioequivalence Study
I-57 Willem de Winter Dynamics of a Two-Receptor Binding Model: How Affinities and Capacities Translate into Long- and Short-Term Behaviour and Physiological Corollaries
I-59 Ivan Demin Longitudinal model-based meta-analysis in rheumatoid arthritis: an application towards model based drug development
I-61 Vincenzo Luca Di Iorio Application of Stochastic Differential Equations to Disease Progression in a Neuropathic Pain Model in Rats
II-2 Anne Dubois Pharmacokinetic bioequivalence analysis of biologics using nonlinear mixed effects modeling
II-3 Anne Dubois Clinical trial simulations to design a crossover study assessing the equivalence on the pharmacodynamic surrogate marker between an immediate and a modified release formulations
II-10 Charles Ernest Multinomial Markov-chain model of sleep architecture in Phase-Advanced Subjects (PAS)
II-15 Martin Fink Diversity: Academia-Industry Collaborations on Modeling and Simulation to enhance Scientific Capability Development – The Novartis Experience
II-21 Sathej Gopalakrishnan Population PK/PD evaluation of the effect of dienogest on Hoogland Score in young healthy women
II-37 Manish Gupta Application of Two-Target Quasi-Steady-State (QSS) Model in Population Pharmacokinetic and Pharmacodynamic (PK-PD) Modeling of MNRP1685A in Cynomolgus Monkeys
II-38 Serge Guzy Optimizing The Entire Drug Development Process Using Pharmacometric Tools: From Preclinical To Marketing
II-50 Candice Jamois Title Pharmacokinetic-Pharmacodynamic Modeling of the Relationship between Aleglitazar Exposure and Lipids Response in Type 2 Diabetes Patients.
II-51 Hyewon Jeon A Population Pharmacokinetic/pharmacodynamic Approache of Drug X in Healthy Korean
II-59 Thomas Kerbusch Phase 2b dose selection for the treatment of autoimmune disorders leveraging comparator data
III-13 Lay Ahyoung Lim Development of a longitudinal model for characterizing adverse events of psychiatric drugs in routine clinical care
III-22 Hugh McDevitt Technology Roadmap to Support Model Based Drug Development
III-27 Enrica Mezzalana Title: Quantitative Assessment of First Night Effect in a Polysomnographic Insomnia Study through a Multinomial Mixed-Effect Markov-Chain Model
III-31 Flora Musuamba-Tshinanu KPD modelling of trough FEV1 in chronic obstructive pulmonary disease (COPD).
III-44 Zinnia Parra Target Mediated Drug Disposition Model to Describe the Expression and Kinetics of IL12 And IFNγ in Gene Therapy
III-52 Olivier Petricoul From Animal to Human with a new monoclonal antibody: An example of the use of pharmacokinetics only to assist on the choice of first in human dose.
III-57 Gregory Pinault A structured approach to industrialize the data sourcing to support model based drug development
III-65 Martijn Ruppert Population PK/PD Modeling of a Hepatitis C NS3 Inhibitor
IV-2 Tarjinder Sahota Parameterisation of biomarker response in the assessment of long term safety
IV-7 Yi SoJeong Population Pharmacokinetics of a Novel Proton Pump Inhibitor, Drug Y, in Healthy Volunteers
IV-13 Andreas Steingoetter A population pharmacokinetic model for Gd-DTPA in DCE-MRI
IV-22 David Ternant Influence of the FcγRIIIa genetic polymorphism on the effect of antithymocyte globulins on lymphocyte populations in kidney transplantation
IV-26 Dorota Tomalik-Scharte Evaluation of Circadian Rhythms in Hepatic CYP3A4 Activity Using Population Pharmacokinetics of Midazolam
IV-32 Venkata Pavan Kumar Vajjah Application of pharmacometric principles to quantify the effect of decontamination on the pharmacokinetics, pharmacodynamics and event times of venlafaxine in overdose
IV-49 Pawel Wiczling Pharmacokinetics and Pharmacodynamics of Propofol in ASA III Patients Undergoing Abdominal Aortic Surgery
IV-52 Dan Wright Development of a Bayesian forecasting method for warfarin dose individualisation
IV-53 Rujia Xie Model based meta-analysis (MBMA) to support the development of decision criteria in dental pain studies
IV-55 Shuying Yang Predicting long term Placebo response based on short term observations:Meta-Analysis on FEV1 Response in Asthma Trials

Posters: Other topics - Methodology

I-11 Paul Baverel A novel covariate search method intended for PKPD models with nonparametric parameter distributions
I-13 Benoît Beck From the Experimental Model Settings to the Physical System for Interpretable Decision Making
I-17 Julie Bertrand Multiple SNP analysis with HyperLasso in Pharmacogenetic Studies using Nonlinear Mixed Effects Models
I-18 Bruno Bieth Using a Systems Biology Approach to Explore Clinical Diversity and Investigate Mechanism of Drug Action: Example of the RAAS System in Hypertension
I-19 Roberto Bizzotto Drug Effects on Sleep Data from a 28-Day Clinical Study in Insomniac Patients: Covariate Analysis Using a Multinomial Mixed-Effect Markov-Chain Model
I-20 Marcus Björnsson Performance of non-linear mixed effects models with and without taking informative dropout into account
I-25 Massoud Boroujerdi A Negative feedback model for a mechanism based description of longitudinal observations: application for bone turnover biomarkers.
I-26 Marion Bouillon-Pichault Modeling Pain score in clinical trials using a joint survival-longitudinal mixed model with a Beta distribution in presence of missing values not occurring at random.
I-31 Anne Brochot Specifying Models with Time Dependent Pharmacokinetic Parameters in NONMEM
I-33 Vincent Buchheit Efficient quality review for modeling input dataset
I-42 Marylore Chenel BSA-adjusted dose? An old method to fight old bias
I-43 S. Y. Amy Cheung Structural identifiability of parallel pharmacokinetic experiments as constrained systems
I-52 Emmanuelle Comets A comparison of bootstrap approaches for estimating standard errors of parameters in linear mixed effects models
I-53 Carolyn Coulter Utilising prior literature population models to inform clinical practice - a dosing regimen for immediate N-acetyl cysteine treatment of paracetamol overdose
I-55 Roosmarijn De Cock Maturation of GFR in preterm and term neonates reflected by clearance of different antibiotics
I-58 Maud Delattre Pharmacokinetics and stochastic differential equations : model and methodology.
I-64 Aris Dokoumetzidis Numerical solution of nonlinear fractional compartmental systems
I-65 Aris Dokoumetzidis Multiple dosing for linear fractional pharmacokinetic systems
II-13 Axel Facius Modelling and Simulation based Techniques to support Trial Design and Submission of Daxas 
II-19 Christina Friedrich Comparison of Statistical and Physiological Modeling Methods Using Examples in Drug Discovery and Development
II-47 Vijay Ivaturi Selection Bias in Pre-Specified Covariate Models
II-53 Åsa Johansson Comparison of methods for handling missing covariate data
II-57 Takayuki Katsube Evaluation of Stepwise Covariate Model Building Combined with Cross-Validation
II-58 Ron Keizer The bootstrap of Stepwise Covariate Modeling using linear approximations
II-62 Akash Khandelwal Influence of Correlated Covariates on Predictive Performance for Different Models
III-11 Natacha Lenuzza Development of a PK library of parent drug/metabolite integrated models
III-18 Eleonora Marostica Population state-space modelling of patient responses in antidepressant studies
III-19 Hafedh Marouani Kinetic nomograms assist individualization of drug regimens
III-23 Christophe Meille PK/PD Model of skin toxicity in animal reported as binary outcome
III-60 Klaas Prins Modeling urge urinary incontinence data acknowledging non-Poisson dispersion of counts within individual provides a major model fit improvement.
III-61 Klaas Prins Use of a generalized poisson model to describe micturition frequency in patients with overactive bladder disease.
IV-1 Alberto Russu Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression
IV-14 Doerthe Steller Extension of Continuous-Time PK/PD Markov Models to Published Count Data
IV-23 Nadia Terranova A non parametric population approach for selecting biomarkers of a drug action
IV-25 Michel Tod A meta-analysis regression model for quantitative prediction of the impact of polymorphism on drug exposure
IV-29 Kuenhi Tsai Evaluating Bootstrap Methods in Nonlinear Mixed Effect Models (NMEM) Using a PK Model
IV-48 Thomas Wendl Modeling of renal failure, dialysis, inhalation and mechanical ventilation: Development of a whole-body physiologically-based pharmacokinetic (PBPK) model for ICU patients with and without renal failure receiving inhalatively administered Amikacin via a t

Posters: Paediatrics

I-1 Leon Aarons Population Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and Children
I-4 Hesham Al-Sallami A semi-mechanistic model for estimating lean body weight in children
I-27 Marion Bouillon-Pichault Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4
I-36 Massimo Cella Implementation of Pharmacokinetic Bridging for Drug Combinations in Children
I-38 Pascal Chanu A dose selection rationale based on hemodynamics for sildenafil in pediatric patients with pulmonary arterial hypertension (PAH)
I-48 Karina Claaßen Evaluation of a PBPK Model for Preterm Neonates by Predicting Paracetamol Pharmacokinetics
II-5 Cyrielle Dumont Design optimisation of a pharmacokinetic study in the paediatric development of a drug
II-8 Esther Encinas Fentanyl pharmacokinetic and pharmacodynamic (PK/PD) estimation in neonates and infants using allometric and ontogeny methods
II-12 David Fabre Population Pharmacokinetics of Alfusozin in children and adolescents
II-32 Andreas Velsing Groth Predicting paediatric PK in order to investigate it
II-39 Anna-Karin Hamberg Predictions of warfarin exposure and INR response in children
II-41 Sarapee Hirankarn Population K-PD Model of Sodium Nitroprusside in Neonates and Children During Anesthesia or Sedation.
II-45 Ibrahim Ince Population PK of midazolam from preterm neonates to adults, a maturation model
II-56 Nastya Kassir An Optimal Sampling Strategy for Tacrolimus in Pediatric Liver Transplant Recipients Based on a Population Pharmacokinetic Model
II-63 Sung Eun Kim Population Pharmacokinetics of Theophylline in Premature Korean Infants
II-64 Holly Kimko Disease-Drug Model of Methylphenidate (MPH) in Children with Attention Deficit Hyperactivity Disorder Via Longitudinal Meta-analysis
III-3 Elke Krekels Maturation of glucuronidation; a system specific property
III-20 Amelie Marsot Population pharmacokinetics of Phenobarbital in neonates and infants.
III-45 Parul Patel Dried Blood Spots and Sparse Sampling: A perfect combination for minimally invasive PK/PD studies in children
III-53 Chiara Piana Impact of non-adherence to antiretroviral therapy in HIV-infected children
IV-10 Ivy Song Dose Selection of Dolutegravir (DTG, S/GSK1349572) in Pediatric Studies
IV-31 Wanchana Ungphakorn Population Pharmacokinetics and Use of Monte Carlo Simulation To Determine Optimal Dosing Regimen of Oral Ciprofloxacin in Paediatric Patients with Severe Malnutrition
IV-33 Pyry Välitalo Pharmacokinetics of Oxycodone in Labouring Women With Preliminary Estimates of Neonatal Exposure
IV-39 Sven van Dijkman Optimal design for a dexmedetomidine pharmacokinetic trial in mechanically ventilated neonates with single organ respiratory failure.
IV-44 Katarina Vucicevic Population Pharmacokinetic Modelling of Amikacin in Neonates
IV-46 Chenguang Wang The allometric exponent for maturation in propofol clearance varies with age
IV-64 Wei Zhao Individualized therapy and Bayesian estimator of ganciclovir exposure after oral administration of valganciclovir in pediatric renal transplant patients

Posters: Study design

I-7 Kristoffersson Anders Optimal design of in vitro time kill curve experiments for the evaluation of antibiotic effects.
I-8 Claus Andersen Trial Sample Size Estimation and Study Design Assessment using Monte Carlo Sampling
I-12 Caroline Bazzoli New features for population design evaluation and optimisation with R functions: PFIM Interface 3.1 and PFIM 3.2
I-34 Núria Buil Bruna The feasibility of model-based exposure calculations in preclinical toxicology
II-4 Anne Dubois Evaluation of designs for biosimilarity crossover trials analysed by nonlinear mixed effects models
II-6 Cyrielle Dumont Design evaluation in nonlinear mixed effect models: influence of covariance between random effects
II-30 Gordon Graham An Application of Optimal Design to Dose Selection and Sample Size Determination with a Negative-Binomial Exposure-Response Model for a Phase IIb Study
II-54 Matts Kågedal Improved study design in phase IIb by the use of optimal design, focusing on the precision of dose finding
III-12 Karl-Heinz Liesenfeld Modeling and simulation to optimise the study design investigating the hemodialysis of dabigatran in patients with end stage renal disease (ESRD)
III-24 France Mentré Comparison of results of the different software for design evaluation in population pharmacokinetics and pharmacodynamics
III-32 Thu Thuy Nguyen Evaluation of Fisher information matrix using Gaussian quadrature in nonlinear mixed effects models: application to dose-response trials
III-33 Thu Thuy Nguyen Designing a dose-response study analysed by nonlinear mixed effects models
III-38 Joakim Nyberg Parallelization in optimal experimental design using PopED
III-39 Joakim Nyberg Population optimal design with correlation using Markov Models
III-59 Italo Poggesi Efficiency criteria generated by optimal design tools should be evaluated in the light of study objectives
III-64 Elba Romero PK/PD sampling design optimization following a sustained release formulation of triptorelin using optimal experimental design
IV-20 Amit Taneja Optimisation of Screening Experiments for the Assessment of Analgesic Effects
IV-24 Donato Teutonico Multivariate patient simulation for clinical trial optimization in COPD
IV-43 Camille Vong Optimal Design of Anticancer Regimens
IV-56 Shuying Yang Using Placebo FEV1 Response to Improve the efficiency of clinical trials in Asthma